Celldex Therapeutics (CLDX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Celldex Therapeutics

NasdaqCM•Healthcare•Biotechnology

$38.24-0.74(-0.02%)After hours

Market Cap

$2.98B

P/S

18959.2x

P/B

4.2x

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

How this company scores

WeakMetricSide Score: 26/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (2/25).

Profitability3/25

Growth2/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 18959.2x5y range 0.2x – 18959.2x

Currently above its 19-quarter median.

P/B · 4.2x5y range 0.0x – 6.4x

Currently above its 19-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.98B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $157,000
Q. Revenue: $22,000
TTM EBITDA: $-322.43M
TTM Op. Income: $-325.83M
Q. Op. Income: $-80.62M
TTM Net Income: $-300.55M
Q. Net Income: $-73.50M
EPS: $-0.94
Shares Out.: $77.84M

$157,000 in TTM revenue declined 97.3% YoY, reaching $22,000 last quarter. TTM EBITDA of $-322.43M and TTM operating income of $-325.83M show growth is flowing through to the bottom line. However, net income is negative at $300.55M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 5 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -362368.2%
Op. Margin: -366468.2%
Net Margin: -334104.5%

Op. margin of -366468.2% is down 357720.6% YoY — costs are rising relative to revenue. Net margin at -334104.5% Over the past year, operating margin is down 4089% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 18959.2x
P/B Ratio: 4.2x

P/S of 18959.2x and P/B of 4.2x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $782.35M
Cash: $47.45M
Long-Term Debt: N/A
Book Value: $714.56M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-57.41M
TTM Free Cash Flow: $-242.10M
FCF Margin: -154207.0%
FCF / Net Income: 0.8

TTM FCF of $-242.10M on $-57.41M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.